Auxiliary Reproductive Innovation Development Forum Enters Its Golden Era Amid Historic Policy Tailwinds and Rising Market Demand

Like a Spring Breeze Overnight: The Assisted Reproductive Technology Sector Surges Once Again.

In 2021, China’s natural population growth rate was 0.34 per thousand, a decline of 1.11 percentage points from 2020, marking the country’s formal entry into an era of zero population growth. Coinciding with this demographic shift is a high prevalence of infertility. Due to the long-standing one-child policy, infertility among older women had been largely overlooked. Following the implementation of the universal two-child policy in 2015, the proportion of births to advanced maternal age mothers (generally defined as pregnant women aged 35 and above) in tertiary hospitals rose from 12.54% in 2015 to 17.43% in 2017. Approximately one in every five or six couples experiences infertility, and assisted reproductive technology (ART) is considered one of the most effective treatments for infertility.

Currently, the three-child policy has not yet shown a significant impact on assisted reproductive technology (ART) services, whereas the two-child policy has had a more pronounced effect, particularly among couples born in the 1970s. Meanwhile, relevant local government departments have recently expressed growing interest in including ART in medical insurance coverage.

Driven by favorable population policies, the assisted reproductive technology (ART) industry is accelerating. Amid rising infertility rates, the ART services market has attracted significant attention, with strong optimism from capital markets. The influx of social capital into the ART sector underscores growing investor confidence in its investment prospects. Based on this,VCBeatCombinationJianshi Bureau Holds "Forum on Innovative Development of Assisted Reproductive Technology"The forum will focus on current hot topics in reproductive medicine, clinical applications and discussions in reproductive medicine, and industry prospects. It will bring together top domestic reproductive experts and industry leaders for exchange and dialogue. Leveraging their keen insights into the industry and professional medical expertise, they will jointly create a premier platform for communication and collaboration in the field of assisted reproduction.

Starting with an analysis of assisted reproductive technology (ART) policies, this forum aims to comprehensively map the industry from upstream to downstream. By integrating recent policy changes, it dissects the opportunities and challenges across each segment and subsector of the value chain, offering forward-looking insights into the future development direction of China’s ART industry.

Top industry leaders will discuss the following issues. Let’s unveil the conference highlights in advance!

—

Forum Name: Forum on Innovative Development in Assisted Reproductive Technology

Forum Time: Morning of June 17, 2022

Forum Organizers: VB100, VCBeat, Artery Orange, VCBeat

Co-organized by:Health Intelligence Bureau

●09:00-09:15

Leader's Address

Li Yuedong | Executive Director of the Chinese Hospital Association, Former Party Secretary of Peking University People's Hospital

Yuan Fengming | Marketing Manager for Maternal and Child Ultrasound, Mindray Medical China Region

Policy Orientation Section

●09:15-09:20

Launch Ceremony of the Report on China's Assisted Reproductive Technology Policies

● 09:20-09:40

Interpretation of the “Analysis of China’s Assisted Reproductive Technology Policies, 2022” Report

Sun Tao | Deputy Editor-in-Chief of Jian Shi Ju 

● 09:40-10:00

Reproductive Medicine and China’s Population Strategy

Liu Jiayin | Former Director of the Reproductive Medicine Center, Jiangsu Province People's Hospital

● 10:00-10:20

The Importance of Assisted Reproductive Technology in the Context of Low Fertility Rates

Kuang Yanping | Director, Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

● 10:20-10:40

Can IVF Become Accessible to the General Public?

Zhang Hanwang | Chief Physician, Reproductive Medicine Center, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Exploration and Practice Section

●10:40-11:00

2022 Assisted Reproductive Technology Industry Research: Policy Dividends Will Become the Driving Force Behind an 800-Billion Market

Fan Xiaoyu | Senior Researcher at VCBeat

●11:00-11:20

Strategic Choices for Non-Public Assisted Reproductive Technology Institutions

Duan Tao | CSO, Jinxin Fertility

●11:20-11:40

Ultrasound Solutions in the Field of Reproduction

Xiao Huiru | Academic Manager, Global Ultrasound Imaging Clinical Academic Department, Mindray Medical

●11:40-12:00

Exploratory Practices in Assisted Reproduction at the He Fangfang Studio

He Fangfang | Founder of the Reproductive Medicine Center at Peking Union Medical College Hospital, Founder of He Fangfang Reproductive Medicine Studio

Contributing Editor: Guo Ye